FTG Bio is focused on the discovery and development of novel agents for oncology and rare disease indications.  FTG Bio is a virtual organization composed of professionals with an accomplished track record of compound identification through approval. 

The Company’s lead asset, FT-1518, is a selective mTOR inhibitor that targets both mTORC1 and mTORC2 while avoiding the PI3K pathway.  This compound has shown remarkable preclinical efficacy and a competitive advantage over other assets with common targets.